<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28280">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01700816</url>
  </required_header>
  <id_info>
    <org_study_id>2010P002801</org_study_id>
    <nct_id>NCT01700816</nct_id>
  </id_info>
  <brief_title>Prevention of Delirium After Bone Marrow Transplantation</brief_title>
  <official_title>Usefulness of Bright Light Therapy in the Prevention of Delirium in Patients Undergoing Hematopoietic Stem Cell Transplant (HSCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Cancer Society, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if using bright light sessions during bone marrow
      transplant can prevent people from developing confusion also known as delirium.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot, double blind randomized study conducted in patients scheduled to undergo
      bone marrow transplant at the Massachusetts General Hospital. The goal of this study is to
      look at the usefulness of bright light therapy in the prevention of delirium in a population
      at high risk for developing this condition.

      Delirium can develop in up to half of the people that undergo bone marrow transplant.
      Symptoms include changes in level of alertness, confusion, and temporary problems with
      memory and attention. In severe cases, it can be accompanied by agitation, paranoia(overly
      suspicious), and hallucinations(seeing or hearing things that are not really there).

      Bright light uses no medication and is often used to treat seasonal affective depression and
      multiple sleep disorders. The light boxes are portable and are placed in front of
      individuals for about 30 minutes every day.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Incidence of delirium (Time to the development of delirium based on meeting criteria on the Delirium Rating Scale and/or Memorial Delirium Assessment Scale)</measure>
    <time_frame>From hospital admission until the date of first documented delirium, assessed up to 28 days post-transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Monday, Wednesday, and Friday assessments will begin after beginning light therapy and include the Delirium Rating Scale-Revised-98 (DRS-98)and Memorial Delirium Assessment Scale (MDAS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length and severity of delirium episodes</measure>
    <time_frame>From first documented episode of delirium until discharge from the hospital, assessed up to 28 days post-transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Monday, Wednesday, and Friday assessments include the Delirium Rating Scale-Revised-98 (DRS-98)and Memorial Delirium Assessment Scale (MDAS); Patients will receive assessments after beginning light therapy until day 28 post-transplant or discharge, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average dose of antipsychotic medications required to manage delirium</measure>
    <time_frame>From admission to hospital to discharge, an expected average of 28 days post-transplant</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>From admission to hospital to discharge,  an expected average of 28 days post-transplant</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications (falls, aspiration, infections, nutritional deficits)</measure>
    <time_frame>From admission to hospital to discharge, an expected average of 28 days post-transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Available and pertinent laboratory data will be collected including serum electrolytes, serum BUN, serum creatinine, TSH, LFTs, CBC with differential, Alkaline phosphatase and urinalysis. These tests are performed as part of routine clinical care on patients undergoing HSCT.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Delirium</condition>
  <arm_group>
    <arm_group_label>Bright light therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2500 Lux gaze directed every morning from 8 am until 8:30 am</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham light</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>&lt;1000 Lux gaze directed every morning from 8 am until 8:30 am</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bright light therapy</intervention_name>
    <description>The light box will be placed vertically on a patient table or bed side 2.5 feet away from the user's eyes daily from 8 am to 8:30 am.</description>
    <arm_group_label>Bright light therapy</arm_group_label>
    <other_name>DL930 Day-Light Classic by Uplift Technologies Inc.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham light</intervention_name>
    <description>The light box will be placed vertically on a patient table or bed side 2.5 feet away from the user's eyes daily from 8 am to 8:30 am.</description>
    <arm_group_label>Sham light</arm_group_label>
    <other_name>DL930 Day-Light Classic by Uplift Tecnologies MODIFIED to create placebo boxes.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 or older

          -  Male or female

          -  Patients scheduled to undergo HSCT

          -  English speaking

        Exclusion Criteria:

          -  Previous history of bipolar affective disorder

          -  On-going delirium

          -  History of substance abuse/dependence within 6 months prior to HSCT

          -  History of invasive melanoma. Patients with a history of basal cell   carcinoma,
             melanoma in situ, or squamous cell carcinoma are permitted to enroll if the lesion(s)
             have been excised with negative margins

          -  History of medical/dermatological conditions that make skin especially sensitive to
             light,such as systemic lupus erythematosus (SLE) and/or porphyria

          -  Eye condition that makes eyes vulnerable to light damage

          -  Concomitant use of medications that increase sensitivity to sunlight, such as the
             herbal supplement St. John's Wort

          -  Established primary insomnia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Fernandez-Robles, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlos Fernandez-Robles, MD</last_name>
    <phone>617-643-2410</phone>
    <email>CFERNANDEZ-ROBLES@PARTNERS.ORG</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Justin Eusebio, MA</last_name>
    <email>jeusebio@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Fernandez-Robles, MD</last_name>
      <phone>617-643-2410</phone>
      <email>CFERNANDEZ-ROBLES@PARTNERS.ORG</email>
    </contact>
    <contact_backup>
      <last_name>William Pirl, MD</last_name>
      <phone>617-724-4800</phone>
      <email>WPIRL@PARTNERS.ORG</email>
    </contact_backup>
    <investigator>
      <last_name>Carlos Fernandez-Robles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Pirl, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kirshner HS. Delirium: a focused review. Curr Neurol Neurosci Rep. 2007 Nov;7(6):479-82. Review.</citation>
    <PMID>17999893</PMID>
  </reference>
  <reference>
    <citation>Minden SL, Carbone LA, Barsky A, Borus JF, Fife A, Fricchione GL, Orav EJ. Predictors and outcomes of delirium. Gen Hosp Psychiatry. 2005 May-Jun;27(3):209-14.</citation>
    <PMID>15882768</PMID>
  </reference>
  <reference>
    <citation>Inouye SK, Schlesinger MJ, Lydon TJ. Delirium: a symptom of how hospital care is failing older persons and a window to improve quality of hospital care. Am J Med. 1999 May;106(5):565-73. Review.</citation>
    <PMID>10335730</PMID>
  </reference>
  <reference>
    <citation>Fricchione GL, Nejad SH, Esses JA, Cummings TJ Jr, Querques J, Cassem NH, Murray GB. Postoperative delirium. Am J Psychiatry. 2008 Jul;165(7):803-12.</citation>
    <PMID>18593786</PMID>
  </reference>
  <reference>
    <citation>Hshieh TT, Fong TG, Marcantonio ER, Inouye SK. Cholinergic deficiency hypothesis in delirium: a synthesis of current evidence. J Gerontol A Biol Sci Med Sci. 2008 Jul;63(7):764-72. Review.</citation>
    <PMID>18693233</PMID>
  </reference>
  <reference>
    <citation>Kalisvaart KJ, de Jonghe JF, Bogaards MJ, Vreeswijk R, Egberts TC, Burger BJ, Eikelenboom P, van Gool WA. Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study. J Am Geriatr Soc. 2005 Oct;53(10):1658-66.</citation>
    <PMID>16181163</PMID>
  </reference>
  <reference>
    <citation>Prakanrattana U, Prapaitrakool S. Efficacy of risperidone for prevention of postoperative delirium in cardiac surgery. Anaesth Intensive Care. 2007 Oct;35(5):714-9.</citation>
    <PMID>17933157</PMID>
  </reference>
  <reference>
    <citation>Liptzin B, Laki A, Garb JL, Fingeroth R, Krushell R. Donepezil in the prevention and treatment of post-surgical delirium. Am J Geriatr Psychiatry. 2005 Dec;13(12):1100-6.</citation>
    <PMID>16319303</PMID>
  </reference>
  <reference>
    <citation>Sampson EL, Raven PR, Ndhlovu PN, Vallance A, Garlick N, Watts J, Blanchard MR, Bruce A, Blizard R, Ritchie CW. A randomized, double-blind, placebo-controlled trial of donepezil hydrochloride (Aricept) for reducing the incidence of postoperative delirium after elective total hip replacement. Int J Geriatr Psychiatry. 2007 Apr;22(4):343-9.</citation>
    <PMID>17006875</PMID>
  </reference>
  <reference>
    <citation>Leung JM, Sands LP, Rico M, Petersen KL, Rowbotham MC, Dahl JB, Ames C, Chou D, Weinstein P. Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients. Neurology. 2006 Oct 10;67(7):1251-3. Epub 2006 Aug 16.</citation>
    <PMID>16914695</PMID>
  </reference>
  <reference>
    <citation>Tabet N, Howard R. Non-pharmacological interventions in the prevention of delirium. Age Ageing. 2009 Jul;38(4):374-9. Epub 2009 May 21. Review.</citation>
    <PMID>19460856</PMID>
  </reference>
  <reference>
    <citation>Inouye SK, Bogardus ST Jr, Charpentier PA, Leo-Summers L, Acampora D, Holford TR, Cooney LM Jr. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med. 1999 Mar 4;340(9):669-76.</citation>
    <PMID>10053175</PMID>
  </reference>
  <reference>
    <citation>Lipowski ZJ. Delirium (acute confusional states). JAMA. 1987 Oct 2;258(13):1789-92.</citation>
    <PMID>3625989</PMID>
  </reference>
  <reference>
    <citation>Shigeta H, Yasui A, Nimura Y, Machida N, Kageyama M, Miura M, Menjo M, Ikeda K. Postoperative delirium and melatonin levels in elderly patients. Am J Surg. 2001 Nov;182(5):449-54.</citation>
    <PMID>11754849</PMID>
  </reference>
  <reference>
    <citation>McIntyre IM, Norman TR, Burrows GD, Armstrong SM. Human melatonin suppression by light is intensity dependent. J Pineal Res. 1989;6(2):149-56.</citation>
    <PMID>2915324</PMID>
  </reference>
  <reference>
    <citation>Petterborg LJ, Kjellman BF, Thalén BE, Wetterberg L. Effect of a 15 minute light pulse on nocturnal serum melatonin levels in human volunteers. J Pineal Res. 1991 Jan;10(1):9-13.</citation>
    <PMID>2056432</PMID>
  </reference>
  <reference>
    <citation>Fortuyn HD, Schoemaker J. Treatment of delirium with phototherapy: a case report. Eur Psychiatry. 1997;12(7):367-8.</citation>
    <PMID>19698553</PMID>
  </reference>
  <reference>
    <citation>Schmitz M, Frey R, Pichler P, Röpke H, Anderer P, Saletu B, Rudas S. Sleep quality during alcohol withdrawal with bright light therapy. Prog Neuropsychopharmacol Biol Psychiatry. 1997 Aug;21(6):965-77.</citation>
    <PMID>9380792</PMID>
  </reference>
  <reference>
    <citation>Taguchi T, Yano M, Kido Y. Influence of bright light therapy on postoperative patients: a pilot study. Intensive Crit Care Nurs. 2007 Oct;23(5):289-97. Epub 2007 Aug 9.</citation>
    <PMID>17692522</PMID>
  </reference>
  <reference>
    <citation>Beglinger LJ, Duff K, Van Der Heiden S, Parrott K, Langbehn D, Gingrich R. Incidence of delirium and associated mortality in hematopoietic stem cell transplantation patients. Biol Blood Marrow Transplant. 2006 Sep;12(9):928-35.</citation>
    <PMID>16920558</PMID>
  </reference>
  <reference>
    <citation>Fann JR, Roth-Roemer S, Burington BE, Katon WJ, Syrjala KL. Delirium in patients undergoing hematopoietic stem cell transplantation. Cancer. 2002 Nov 1;95(9):1971-81.</citation>
    <PMID>12404292</PMID>
  </reference>
  <reference>
    <citation>Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9.</citation>
    <PMID>15817019</PMID>
  </reference>
  <reference>
    <citation>Trzepacz PT, Mittal D, Torres R, Kanary K, Norton J, Jimerson N. Validation of the Delirium Rating Scale-revised-98: comparison with the delirium rating scale and the cognitive test for delirium. J Neuropsychiatry Clin Neurosci. 2001 Spring;13(2):229-42. Erratum in: J Neuropsychiatry Clin Neurosci 2001 Summer;13(3):433.</citation>
    <PMID>11449030</PMID>
  </reference>
  <reference>
    <citation>Breitbart W, Rosenfeld B, Roth A, Smith MJ, Cohen K, Passik S. The Memorial Delirium Assessment Scale. J Pain Symptom Manage. 1997 Mar;13(3):128-37.</citation>
    <PMID>9114631</PMID>
  </reference>
  <reference>
    <citation>Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Markey SP. Light suppresses melatonin secretion in humans. Science. 1980 Dec 12;210(4475):1267-9.</citation>
    <PMID>7434030</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 16, 2013</lastchanged_date>
  <firstreceived_date>October 1, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Carlos Fernandez-Robles</investigator_full_name>
    <investigator_title>Principal Investigator, MD</investigator_title>
  </responsible_party>
  <keyword>Delirium</keyword>
  <keyword>Hematopoietic stem cell transplantation</keyword>
  <keyword>Bone marrow transplantation</keyword>
  <keyword>Bright Light Therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
